Catalyst Pharmaceuticals Inc expected to post earnings of 17 cents a share - Earnings Preview

Catalyst Pharmaceuticals

07/05/2024 03:30

* Catalyst Pharmaceuticals Inc  CPRX.OQ   CPRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 8 for the period ending March 31 2024
    * The Coral Gables Florida-based  company is expected to
report a
14.9% increase in revenue to $98.126 million from $85.37 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data. (Sales is on Total Revenue Basis.)
    * ​LSEG's mean analyst estimate for Catalyst Pharmaceuticals
Inc
is for earnings of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Catalyst
Pharmaceuticals Inc is $26.00​, above​ its last closing price
of $14.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.26        0.27       0.31      Beat    17
 Sep. 30 2023  -0.38       -0.28      -0.29     Missed  -1.8
 Jun. 30 2023  0.42        0.36       0.53      Beat    48.9​
 Mar. 31 2023  0.32        0.32       0.26      Missed  -19.3
 ​​Dec.        0.23        0.21       0.22      Beat    3.8
 31 2022                                                
 Sep. 30 2022  0.19        0.19       0.20      Beat    5.3​
 Jun. 30 2022  0.17        0.17       0.20      Beat    17.6
 Mar. 31 2022  0.14        0.14       0.12      Missed  -11.8
 This summary was machine generated May 7 at 02:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)